➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Harvard Business School
Dow
Merck
AstraZeneca

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022203


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 022203 describes ASTEPRO, which is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ASTEPRO profile page.

The generic ingredient in ASTEPRO is azelastine hydrochloride. There are twelve drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride profile page.
Summary for 022203
Tradename:ASTEPRO
Applicant:Mylan Speciality Lp
Ingredient:azelastine hydrochloride
Patents:3
Formulation / Manufacturing:see details
Pharmacology for NDA: 022203
Suppliers and Packaging for NDA: 022203
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ASTEPRO azelastine hydrochloride SPRAY, METERED;NASAL 022203 NDA Meda Pharmaceuticals 0037-0243 0037-0243-04 1 BOTTLE, SPRAY in 1 BOX (0037-0243-04) > 22 SPRAY, METERED in 1 BOTTLE, SPRAY
ASTEPRO azelastine hydrochloride SPRAY, METERED;NASAL 022203 NDA Meda Pharmaceuticals 0037-0243 0037-0243-30 1 BOTTLE, SPRAY in 1 BOX (0037-0243-30) > 200 SPRAY, METERED in 1 BOTTLE, SPRAY
Paragraph IV (Patent) Challenges for 022203
Tradename Dosage Ingredient NDA Submissiondate
ASTEPRO SPRAY, METERED;NASAL azelastine hydrochloride 022203 2011-12-15

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:SPRAY, METERED;NASALStrengthEQ 0.125MG BASE/SPRAY
Approval Date:Oct 15, 2008TE:RLD:No
Patent:  Start TrialPatent Expiration:Jun 4, 2028Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Nov 22, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SPRAY, METERED;NASALStrengthEQ 0.1876MG BASE/SPRAY
Approval Date:Aug 31, 2009TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Jun 4, 2028Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Baxter
Express Scripts
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.